<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00120419</url>
  </required_header>
  <id_info>
    <org_study_id>MAN2-study</org_study_id>
    <nct_id>NCT00120419</nct_id>
  </id_info>
  <brief_title>Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanquin Research &amp; Blood Bank Divisions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether mycophenolate mofetil (MMF) can treat the
      chronic hyperactivation of the immune system and (partly) prevent the decrease of the CD4+
      T-cell count in chronically HIV-1 infected patients who are not treated with antiretroviral
      therapy (ART). The researchers also want to know what the effect is of treatment with MMF on
      plasma HIV-1 RNA; progression of disease (occurrence of AIDS defining events or reaching the
      indication to start ART); and the safety of treatment with MMF in this patient group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      *Background: During chronic HIV-1 infection the immune system is chronically hyperactivated.
      This hyperactivation is considered as the main cause of CD4+ T-cell loss. Furthermore, HIV
      replicates most efficiently in activated CD4+ T-cells. In this study we try to inhibit the
      activation of the immune system with mycophenolate mofetil (MMF). Previous studies in which
      HIV-1 infected patients have been treated with MMF in addition to antiretroviral treatment
      (ART) have not shown any additional effect, compared to ART alone. In this study MMF will be
      used without antiretroviral medication.

      *Objectives: Primary objective of the study is the evaluation of the effect of MMF on the
      chronic hyperactivation of the immune system and the decrease of the CD4+ T-cell count in
      chronically HIV-1 infected patients who are not treated with antiretroviral therapy (ART).
      Secondary objectives include the evaluation of the effect of MMF on plasma HIV-1 RNA;
      progression of disease/ reaching of indication to start ART; and the safety of treatment with
      MMF in this patient group.

      *Study Design: This is a multi center, randomized, open-label study, in which patients will
      be randomized to treatment with mycophenolate mofetil (MMF) 500 mg BID during 48 weeks versus
      no treatment. In a subgroup of 20 patients (&quot;immunology group&quot;, the first 20 patients in the
      AMC hospital, Amsterdam, the Netherlands) a number of additional immunological measurements
      will be performed.

      The study duration is 60 weeks (48 weeks of treatments with 1 additional visit 12 weeks after
      cessation of treatment).

      *Study Population: Potential participants are adult chronically HIV-1 infected patients, who
      have never been treated with ART and who according to the present criteria do not need to be
      treated. CD4+ T lymphocyte count has to be &gt; 250 and &lt;= 450 * 106/L, plasma HIV-1 RNA (viral
      load) &lt; 10.000 copies/ mL.

      *Intervention: Patients will be randomized (1:1) to mycofenolate mofetil (MMF) 500 mg BID
      versus no treatment.

      *Endpoints: Primary endpoints are change over time (baseline - week 48) in CD4+ T cell count
      and peripheral blood lymphocyte (PBMC) activation markers.

      Secondary endpoints are changes over time (baseline - week 48) in plasma HIV-1 RNA, time to
      reach indication to start ART (separated in three groups: 1. two consecutive measurements of
      CD4+ T cell count below 250 * 106 cells/ L with at least 4 weeks interval; 2. the occurrence
      of a CDC class B or C event; 3. any other reason); safety data.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2005</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change over time (baseline - week 48) in CD4+ cell counts in peripheral blood and peripheral blood lymphocyte activation markers.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>* Change over time (baseline - week 48) in plasma HIV-1 RNA, time to reach an indication to start antiretroviral treatment and safety parameters.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>HIV Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenol mofetil (MMF, Cellcept®) 500 mg BID</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is ≥ 18 years of age;

          -  Patient has a proven HIV-1 infection (with antibodies against HIV-1 and a detectable
             plasma HIV-1 RNA measured for the first time at least 6 months prior to inclusion);

          -  Patient is HIV-1 treatment naïve;

          -  CD4+ T lymphocyte count &gt; 250 and &lt;= 450 * 106/L;

          -  No signs or history of AIDS defining events;

          -  No use of other medications that might possibly influence the effects of MMF;

          -  Male; or female sex and willingness to practice effective contraception during the
             study.

        Exclusion Criteria:

          -  Plasma HIV-1 RNA &lt; 10.000 copies/ mL;

          -  Autoimmune disease;

          -  Active hepatitis B or C virus infection;

          -  Other chronic diseases;

          -  Recent infectious disease other than HIV-1;

          -  Treatment with immunomodulatory or anti-inflammatory medication in the past 6 months;

          -  For female patients: pregnancy and lactation;

          -  Any other condition, illness or use of medication which according to the investigator
             is not compatible with the use of the study medication or which could interfere with
             the evaluations required by the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan M Prins, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kees Brinkman, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>department of internal medicine, OLVG hospital, Amsterdam, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin Soetekouw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>department of internal medicine, Kennemer Gasthuis, Haarlem, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Kauffmann, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, HAGA hospital, location Leyenburg Hospital, The Hague, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joost N Vermeulen, MD</last_name>
    <phone>+31 20 5668992</phone>
    <email>j.n.vermeulen@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan M Prins, MD PhD</last_name>
    <phone>+31 20 5669111</phone>
    <email>j.m.prins@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <state>NH</state>
        <zip>1091AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucie Schrijnders-Gudde</last_name>
      <phone>+31 20 5999111</phone>
      <phone_ext>4626</phone_ext>
      <email>L.Schrijnders-Gudde@olvg.nl</email>
    </contact>
    <investigator>
      <last_name>Kees Brinkman, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>H. M. Weigel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>P. H. Frissen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>W. E. Schouten, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>NH</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joost N Vermeulen, MD</last_name>
      <phone>+31 20 5668992</phone>
      <email>j.n.vermeulen@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jan M Prins, MD PhD</last_name>
      <phone>+31 20 566 9111</phone>
      <email>j.m.prins@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Jan M Prins, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joost N Vermeulen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis, location EG</name>
      <address>
        <city>Haarlem</city>
        <state>NH</state>
        <zip>2035RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robin Soetekouw, MD</last_name>
      <phone>+31 23 5453545</phone>
      <email>soetekou@KG.NL</email>
    </contact>
    <investigator>
      <last_name>Robin Soetekouw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>ZH</state>
        <zip>3015GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iman Padmos</last_name>
      <phone>+31 (0)10-4635737</phone>
      <email>i.padmos@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Ineke van der Ende, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HAGA hospital, location Leyenburg Hospital</name>
      <address>
        <city>The Hague</city>
        <state>ZH</state>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert H Kauffmann, MD PhD</last_name>
      <phone>+31 70-3592007</phone>
      <email>r.kauffmann@leyenburg-ziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Anneke van IJperen</last_name>
      <phone>+31 70-3592414</phone>
      <email>j.maat@leyenburg-ziekenhuis.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Robert H Kauffman, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Chapuis AG, Paolo Rizzardi G, D'Agostino C, Attinger A, Knabenhans C, Fleury S, Acha-Orbea H, Pantaleo G. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med. 2000 Jul;6(7):762-8.</citation>
    <PMID>10888924</PMID>
  </reference>
  <reference>
    <citation>Sankatsing SU, Jurriaans S, van Swieten P, van Leth F, Cornelissen M, Miedema F, Lange JM, Schuitemaker H, Prins JM. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS. 2004 Sep 24;18(14):1925-31.</citation>
    <PMID>15353978</PMID>
  </reference>
  <reference>
    <citation>García F, Plana M, Arnedo M, Brunet M, Castro P, Gil C, Vidal E, Millán O, López A, Martorell J, Fumero E, Miró JM, Alcamí J, Pumarola T, Gallart T, Gatell JM. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):823-30.</citation>
    <PMID>15213566</PMID>
  </reference>
  <verification_date>January 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2005</study_first_submitted>
  <study_first_submitted_qc>July 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2005</study_first_posted>
  <last_update_submitted>July 21, 2009</last_update_submitted>
  <last_update_submitted_qc>July 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2009</last_update_posted>
  <keyword>HIV-1 infection</keyword>
  <keyword>immunomodulatory therapy</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

